

Violeta Sanchez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/784754/publications.pdf>

Version: 2024-02-01

26
papers

2,091
citations

430874

18
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

4511
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer. , 2021, , .		0
2	Abstract PS4-19: Evaluation of tumor-specific MHC-II expression as a biomarker. , 2021, , .		0
3	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. Journal of Clinical Investigation, 2021, 131, .	8.2	11
4	Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell Death and Disease, 2021, 12, 745.	6.3	13
5	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-“PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clinical Cancer Research, 2021, 27, 5299-5306.	7.0	39
6	245“...Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. , 2021, 9, A264-A264.		0
7	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clinical Cancer Research, 2020, 26, 5668-5681.	7.0	37
8	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine, 2020, 12, .	12.4	46
9	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	30.7	133
10	Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. Cancer Research, 2019, 79, 171-182.	0.9	57
11	Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers. Oncotarget, 2019, 10, 5389-5402.	1.8	18
12	DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nature Communications, 2018, 9, 248.	12.8	181
13	Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death and Disease, 2018, 9, 21.	6.3	16
14	Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Research, 2018, 78, 1845-1858.	0.9	54
15	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncolmmunology, 2018, 7, e1438106.	4.6	54
16	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research, 2017, 77, 2488-2499.	0.9	178
17	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research, 2017, 77, 3280-3292.	0.9	76
18	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Molecular Cancer Research, 2017, 15, 259-268.	3.4	40

#	ARTICLE	IF	CITATIONS
19	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. <i>Cell Metabolism</i> , 2017, 26, 633-647.e7.	16.2	449
20	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
21	Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. <i>Breast Cancer Research</i> , 2017, 19, 74.	5.0	55
22	Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer. <i>Molecular Imaging and Biology</i> , 2017, 19, 130-137.	2.6	24
23	ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. <i>Breast Cancer Research</i> , 2017, 19, 105.	5.0	23
24	Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast Cancers. <i>Cancer Research</i> , 2016, 76, 4752-4764.	0.9	71
25	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015, 6, 22348-22360.	1.8	12
26	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245.	9.4	413